Tiziana Life Sciences
Price & Volume
Stats
See moreOpen | $2.06 |
Previous Close | $2 |
Day Range | $1.92-$2.08 |
52W Range | $0.62-$2.60 |
Market Cap | $233.6M |
Shares Short | 582,954 |
Financials
See moreRevenue (12 Mos) | -$3.5M |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$0.11 |
News
See moreYahoo Finance • 2 days ago
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
Yahoo Finance • last month
Tech Voices: OpenAI warns on stock tokens, CoreWeave-Nvidia, Apple
Yahoo Finance • 2 months ago
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
Yahoo Finance • 2 months ago
Tiziana shares rise on presentation date for foralumab data
About
CEO | Dr. Ivor R. Elrifi Ph.D. |
CFO | Ms. Keeren Shah |
Address | 14/15 Conduit Street, London, United Kingdom, W1S 2XJ |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 9 |
